• Recruiting

NCT03556332: Phase 2 - Carfilzomib, Lenalidomide, Dex Daratumumab for relap. MM with auto transplant

Updated: May 28

A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

Dara-KRd

The purpose of this study is to test any good and bad effects of giving a combination of study drugs before and after autologous stem cell transplant.


Sponsor

Memorial Sloan Kettering Cancer Center


Collaborator

Janssen Pharmaceuticals

 

ClinicalTrials.gov Identifier: NCT03556332


Official Title: Phase 2 Trial of Intensive Chemo-immunotherapy With Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed/Refractory Myeloma in the Context of Salvage Autologous Hematopoietic Cell Transplantation

First Posted : June 14, 2018

Click here for details on ClinicalTrials.gov

 

Daratumumab : National Cancer Institute

Daratumumab : MedlinePlus Drug Information


Carfilzomib : National Cancer Institute

Carfilzomib : MedlinePlus Drug Information


Lenalidomide: National Cancer Institute

Lenalidomide: MedlinePlus Drug Information


Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information

 

* Carfilzomib (Kyprolis)

* Lenalidomide (Revlimid)

* Dexamethasone (Decadron)

* Daratumumab (Darzalex)

 

- New York: Memorial Sloan-Kettering Cancer Center New York

- Alabama: University of Alabama at Birmingham

 

Locations

United States, Alabama

United States, New Jersey

United States, New York

United States, North Carolina

United States, Wisconsin




Posts Archive